Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: A 52-week, randomized, open-label extension of the PIONEER 7 trial

UNC Libraries(2024)10.17615/7bmd-2j28Source: DataRank Database

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: A 52-week, randomized, open-label extension of the PIONEER 7 trial is a research paper published in UNC Libraries (2024). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.00)OA: greenTopics (35)IDs (PubMed, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Hertz C.L,Ann Mertens ORCID,Erik Christiansen ORCID,Pieber T.R,Nielsen M.A

Live enrichment

PubMed:26657633 OpenAlex:https://openalex.org/W4400034295

National Institutes of Health

Grant: 3UL1TR002489-02S1

North Carolina Translational and Clinical Science Institute (NC TraCS)

National Institutes of Health

Grant: 1P30DK124723-01

North Carolina Diabetes Research Center

FWCI

0.00

Citation Percentile

0.2%

greenLicense: CC BY NC

repositoryhttps://doi.org/10.17615/7bmd-2j28

https://doi.org/10.1136/bmjdrc-2020-001649

https://drc.bmj.com/content/bmjdrc/8/2/e001649.full.pdf

https://dx.doi.org/10.17615/7bmd-2j28

https://pubmed.ncbi.nlm.nih.gov/33318068

Fields of Study

Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerInflammatory mediators and NSAID effects03 medical and health sciences0302 clinical medicine

Keywords

SemaglutideSitagliptinMedicineType 2 diabetesInternal medicineEndocrinologyDiabetes mellitusGlucagon-Like PeptidesAdministration, OralDiseases of the endocrine glands. Clinical endocrinologyEndocrinology & Metabolismdipeptidyl peptidase 4PIONEER 7 investigatorsMANAGEMENTHumansHypoglycemic AgentsScience & TechnologyJAPANESE PATIENTSSitagliptin Phosphate3202 Clinical sciences1103 Clinical SciencesASSOCIATIONEmerging Technologies, Pharmacology and TherapeuticsRC648-665glucagon-like peptide 14206 Public healthDiabetes Mellitus, Type 2treatment outcomePEPTIDE-1 RECEPTOR AGONISTSLife Sciences & Biomedicine

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 0: Good health and well-being